- Home
- VSTA vs CHRS Comparison
VSTA vs CHRS Comparison
Compare VSTA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTA
- CHRS
- Stock Information
- Founded
- VSTA 1966
- CHRS 2010
- Country
- VSTA Brazil
- CHRS United States
- Employees
- VSTA N/A
- CHRS 235
- Industry
- VSTA Other Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTA Real Estate
- CHRS Health Care
- Exchange
- VSTA Nasdaq
- CHRS Nasdaq
- Market Cap
- VSTA 187.6M
- CHRS 134.4M
- IPO Year
- VSTA 2020
- CHRS 2014
- Fundamental
- Price
- VSTA $2.71
- CHRS $1.22
- Analyst Decision
- VSTA Sell
- CHRS Strong Buy
- Analyst Count
- VSTA 2
- CHRS 4
- Target Price
- VSTA $3.00
- CHRS $5.38
- AVG Volume (30 Days)
- VSTA 17.4K
- CHRS 2.4M
- Earning Date
- VSTA 03-19-2025
- CHRS 03-12-2025
- Dividend Yield
- VSTA N/A
- CHRS N/A
- EPS Growth
- VSTA N/A
- CHRS N/A
- EPS
- VSTA N/A
- CHRS N/A
- Revenue
- VSTA $280,865,717.00
- CHRS $304,340,000.00
- Revenue This Year
- VSTA $13.03
- CHRS $2.47
- Revenue Next Year
- VSTA $9.88
- CHRS N/A
- P/E Ratio
- VSTA N/A
- CHRS N/A
- Revenue Growth
- VSTA 6.41
- CHRS 44.19
- 52 Week Low
- VSTA $1.60
- CHRS $0.66
- 52 Week High
- VSTA $4.15
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- VSTA 58.16
- CHRS 44.03
- Support Level
- VSTA $2.50
- CHRS $1.03
- Resistance Level
- VSTA $2.90
- CHRS $1.23
- Average True Range (ATR)
- VSTA 0.17
- CHRS 0.13
- MACD
- VSTA 0.02
- CHRS -0.02
- Stochastic Oscillator
- VSTA 65.11
- CHRS 38.89
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.